Inclisiran: Government's strategy to promote cholesterol lowering drug after Brexit was "spectacular failure," says insider
The government’s policy to fast track “innovative” drugs into the NHS to showcase the UK as a great place for industry has been described as “a pretty spectacular failure,” because of the way a test case using the cholesterol lowering drug inclisiran was received. The rapid introduction of inclisiran into the UK was part of the government’s drive to help the country regain its “status as a science superpower” after Brexit,1 which would bypass some of the usual routes to getting a drug into clinical practice. The policy was widely supported across government, including by the De...
Source: bmj.com
